Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral Sclerosis

NCT02655614 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02655614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02655614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral Sclerosis
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2016
Completion date
March 16, 2020
Enrollment
54 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis